Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP-3070 in Schizophrenia
NCT02876900Phase 3Completed
- Sponsor
- Noven Pharmaceuticals
- Start
- Aug 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Secuado in schizophrenia, sponsored by Noven Pharmaceuticals. Started Aug 2016; status: completed.
02
Drugs
Secuado
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02876900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02876900.